Thermo Fisher Scientific Inc. (TMO) Director Sells $209,800.00 in Stock

Thermo Fisher Scientific Inc. (NYSE:TMO) Director William G. Parrett sold 1,000 shares of the business’s stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $209.80, for a total transaction of $209,800.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Shares of Thermo Fisher Scientific Inc. (NYSE TMO) opened at $207.84 on Wednesday. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.92 and a current ratio of 1.35. The firm has a market cap of $83,340.00, a P/E ratio of 34.07, a P/E/G ratio of 1.54 and a beta of 1.11. Thermo Fisher Scientific Inc. has a 12 month low of $151.74 and a 12 month high of $226.44.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, January 31st. The medical research company reported $2.79 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.66 by $0.13. The business had revenue of $6.05 billion during the quarter, compared to the consensus estimate of $5.72 billion. Thermo Fisher Scientific had a net margin of 10.64% and a return on equity of 16.01%. Thermo Fisher Scientific’s revenue for the quarter was up 22.1% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.41 earnings per share. analysts predict that Thermo Fisher Scientific Inc. will post 10.81 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Monday, April 16th. Investors of record on Thursday, March 15th will be paid a dividend of $0.17 per share. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.33%. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.15. The ex-dividend date of this dividend is Wednesday, March 14th. Thermo Fisher Scientific’s payout ratio is 9.84%.

Several institutional investors and hedge funds have recently bought and sold shares of TMO. Vanguard Group Inc. increased its stake in Thermo Fisher Scientific by 2.4% in the second quarter. Vanguard Group Inc. now owns 26,600,394 shares of the medical research company’s stock valued at $4,640,970,000 after purchasing an additional 629,093 shares in the last quarter. Capital Research Global Investors increased its stake in Thermo Fisher Scientific by 29.8% in the second quarter. Capital Research Global Investors now owns 17,304,897 shares of the medical research company’s stock valued at $3,019,185,000 after purchasing an additional 3,973,136 shares in the last quarter. Capital World Investors increased its stake in Thermo Fisher Scientific by 6.1% in the second quarter. Capital World Investors now owns 11,759,734 shares of the medical research company’s stock valued at $2,051,721,000 after purchasing an additional 671,637 shares in the last quarter. Longview Partners Guernsey LTD increased its stake in Thermo Fisher Scientific by 6.8% in the fourth quarter. Longview Partners Guernsey LTD now owns 4,876,890 shares of the medical research company’s stock valued at $926,024,000 after purchasing an additional 311,977 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in Thermo Fisher Scientific by 4.2% in the fourth quarter. Geode Capital Management LLC now owns 3,917,221 shares of the medical research company’s stock valued at $742,108,000 after purchasing an additional 158,961 shares in the last quarter. 86.54% of the stock is owned by institutional investors and hedge funds.

A number of equities analysts have weighed in on the stock. Barclays boosted their target price on shares of Thermo Fisher Scientific from $225.00 to $245.00 and gave the stock an “overweight” rating in a research note on Thursday, February 1st. Leerink Swann reaffirmed an “outperform” rating and issued a $239.00 target price (up from $200.00) on shares of Thermo Fisher Scientific in a research note on Thursday, February 1st. They noted that the move was a valuation call. Bank of America boosted their target price on shares of Thermo Fisher Scientific from $235.00 to $250.00 and gave the stock a “buy” rating in a research note on Thursday, February 1st. Zacks Investment Research raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $215.00 target price for the company in a research note on Tuesday, October 31st. Finally, Morgan Stanley boosted their target price on shares of Thermo Fisher Scientific from $223.00 to $227.00 and gave the stock an “overweight” rating in a research note on Thursday, February 1st. Two equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $220.50.

TRADEMARK VIOLATION NOTICE: This article was posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this article on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The original version of this article can be viewed at https://www.thelincolnianonline.com/2018/02/21/thermo-fisher-scientific-inc-tmo-director-sells-209800-00-in-stock.html.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Insider Buying and Selling by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply